- Home
- LSTA vs NRBO Comparison
LSTA vs NRBO Comparison
Compare LSTA & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- NRBO
- Stock Information
- Founded
- LSTA 1980
- NRBO N/A
- Country
- LSTA United States
- NRBO United States
- Employees
- LSTA N/A
- NRBO N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- NRBO Health Care
- Exchange
- LSTA Nasdaq
- NRBO Nasdaq
- Market Cap
- LSTA 24.2M
- NRBO 27.9M
- IPO Year
- LSTA N/A
- NRBO N/A
- Fundamental
- Price
- LSTA $2.85
- NRBO $2.19
- Analyst Decision
- LSTA Strong Buy
- NRBO Strong Buy
- Analyst Count
- LSTA 1
- NRBO 1
- Target Price
- LSTA $15.00
- NRBO $10.00
- AVG Volume (30 Days)
- LSTA 15.2K
- NRBO 35.2K
- Earning Date
- LSTA 11-12-2024
- NRBO 11-07-2024
- Dividend Yield
- LSTA N/A
- NRBO N/A
- EPS Growth
- LSTA N/A
- NRBO N/A
- EPS
- LSTA N/A
- NRBO N/A
- Revenue
- LSTA N/A
- NRBO N/A
- Revenue This Year
- LSTA N/A
- NRBO N/A
- Revenue Next Year
- LSTA N/A
- NRBO N/A
- P/E Ratio
- LSTA N/A
- NRBO N/A
- Revenue Growth
- LSTA N/A
- NRBO N/A
- 52 Week Low
- LSTA $2.05
- NRBO $2.08
- 52 Week High
- LSTA $3.83
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- LSTA 46.05
- NRBO 31.67
- Support Level
- LSTA $2.75
- NRBO $2.37
- Resistance Level
- LSTA $2.94
- NRBO $2.99
- Average True Range (ATR)
- LSTA 0.21
- NRBO 0.31
- MACD
- LSTA -0.01
- NRBO -0.03
- Stochastic Oscillator
- LSTA 23.08
- NRBO 0.62
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.